arrow
Y

Yu Noda

kurume university
H指数:17
被引数:926

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
2023-02-246
OAAI
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data

使用真实世界数据,阿特珠单抗联合贝伐单抗治疗肝细胞癌后雷莫昔单抗的意义

2022-11-167
PRE
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma
2022-11-0622
PRE
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
2022-10-118
OAAI
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching
2019-05-1348
PREAI